

Atara Biotherapeutics, Inc.  
Form 8-K  
September 23, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**  
**the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): September 22, 2016**

**Atara Biotherapeutics, Inc.**

**(Exact name of Registrant as Specified in Its Charter)**

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**001-36548**  
**(Commission**  
  
**File Number)**

**46-0920988**  
**(IRS Employer**  
  
**Identification No.)**

**611 Gateway Blvd., Suite 900**

**South San Francisco, CA**  
**(Address of Principal Executive Offices)**

**94080**  
**(Zip Code)**

**Registrant's Telephone Number, Including Area Code: (650) 278-8930**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On September 22, 2016, the Compensation Committee of the Board of Directors of Atara Biotherapeutics, Inc. ( *Atara* ) approved a base salary increase for Heather D. Turner in connection with an increase in her responsibilities at Atara. Effective October 1, 2016, Ms. Turner's base salary will increase from \$342,990 to \$355,350.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Atara Biotherapeutics, Inc.  
(Registrant)

By: /s/ Isaac Ciechanover  
Isaac Ciechanover  
Chief Executive Officer

Date: September 23, 2016